AR107398A1 - Compuestos de 2-oxindol - Google Patents
Compuestos de 2-oxindolInfo
- Publication number
- AR107398A1 AR107398A1 ARP170100150A ARP170100150A AR107398A1 AR 107398 A1 AR107398 A1 AR 107398A1 AR P170100150 A ARP170100150 A AR P170100150A AR P170100150 A ARP170100150 A AR P170100150A AR 107398 A1 AR107398 A1 AR 107398A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- group
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde Ar es un anillo aromático o heteroaromático de entre 5 y 10 miembros, opcionalmente sustituido con entre uno y tres R³; L¹ se selecciona entre el grupo que consiste en una unión, C₁₋₆ alquileno, y C₁₋₆ heteroalquileno; L² se selecciona entre el grupo que consiste en una unión, C₁₋₆ alquileno, y C₁₋₆ heteroalquileno; Y es CO₂H o un bioisóstero de ácido carboxílico; cada R¹ y cada R²ᵃ se selecciona en forma independiente entre el grupo que consiste en halógeno, ciano, C₁₋₆ alquilo, C₁₋₆ alcoxi, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxi, C₃₋₆ cicloalquilo, y C₂₋₆ alquenilo, donde las unidades alquilo, cicloalquilo y alquenilo están opcionalmente sustituidas con entre uno y tres miembros seleccionados entre fluoro, OH, CN, C₁₋₃ alquilo, C₁₋₃ haloalquilo, y C₁₋₃ alcoxi; R²ᵇ se selecciona entre el grupo que consiste en H, halógeno, ciano, C₁₋₆ alquilo, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, y C₂₋₆ alquenilo, donde las unidades alquilo, cicloalquilo y alquenilo están opcionalmente sustituidas con entre uno y tres miembros seleccionados entre fluoro, CN, C₁₋₃, alquilo, C₁₋₃ haloalquilo, y C₁₋₃ alcoxi; u opcionalmente un R²ᵃ y R²ᵇ cuando se encuentran en vértices adyacentes de un anillo fenilo pueden unirse para formar un anillo heterocicloalquilo de 5 ó 6 miembros que tiene uno o dos vértices del anillo seleccionados en forma independiente entre O, N y S, donde dicho anillo heterocicloalquilo está opcionalmente sustituido con entre uno y tres miembros seleccionados entre fluoro y C₁₋₃ alquilo; cada R³ se selecciona en forma independiente entre el grupo que consiste en halógeno, ciano, C₁₋₆ alquilo, C₁₋₆ alcoxi, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxi, C₃₋₆ cicloalquilo, y C₂₋₆ alquenilo; el subíndice m es un entero entre 0 y 4; y el subíndice n es un entero entre 0 y 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662280969P | 2016-01-20 | 2016-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107398A1 true AR107398A1 (es) | 2018-04-25 |
Family
ID=59314376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100150A AR107398A1 (es) | 2016-01-20 | 2017-01-19 | Compuestos de 2-oxindol |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20170204087A1 (es) |
| EP (1) | EP3405455B1 (es) |
| JP (1) | JP6898334B6 (es) |
| KR (1) | KR102799183B1 (es) |
| CN (1) | CN108698991B (es) |
| AR (1) | AR107398A1 (es) |
| AU (1) | AU2017209023B2 (es) |
| BR (1) | BR112018014666B1 (es) |
| ES (1) | ES2985738T3 (es) |
| IL (1) | IL260635B (es) |
| MA (1) | MA43799A (es) |
| MX (1) | MX378739B (es) |
| NZ (1) | NZ744468A (es) |
| RU (1) | RU2743747C2 (es) |
| SG (1) | SG11201806153QA (es) |
| TW (1) | TWI729059B (es) |
| WO (1) | WO2017127409A1 (es) |
| ZA (1) | ZA201804966B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108698991B (zh) | 2016-01-20 | 2022-08-23 | 凯莫森特里克斯股份有限公司 | 2-氧代吲哚化合物 |
| WO2019246312A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| PH12022550877A1 (en) | 2019-10-16 | 2023-03-27 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| BR112022006018A2 (pt) | 2019-10-16 | 2022-07-12 | Chemocentryx Inc | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 |
| WO2021079679A1 (ja) * | 2019-10-21 | 2021-04-29 | 信越化学工業株式会社 | 感光性樹脂組成物、感光性ドライフィルム及びパターン形成方法 |
| KR20220093330A (ko) * | 2019-10-31 | 2022-07-05 | 이도르시아 파마슈티컬스 리미티드 | Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합 |
| CN118556073A (zh) * | 2021-10-06 | 2024-08-27 | 维罗治疗有限公司 | 新型免疫调节剂 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| FR2714378B1 (fr) * | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
| DE69718968T2 (de) | 1996-01-17 | 2003-10-09 | Taiho Pharmaceutical Co. Ltd., Tokio/Tokyo | 3-(bis-substituierte-phenylmethylen)oxindol-derivate |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| FR2807038B1 (fr) * | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| US7250442B2 (en) | 2002-03-15 | 2007-07-31 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| DE60314175T2 (de) * | 2002-11-18 | 2008-01-24 | Chemocentryx Inc., Mountain View | Arylsulfonamide |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| RU2009117642A (ru) | 2006-10-12 | 2010-11-20 | Ксенон Фармасьютикалз Инк. (Ca) | Применение спирооксиндоловых соединений в качестве терапевтических средств |
| FR2909668B1 (fr) * | 2006-12-12 | 2009-01-23 | Sanofi Aventis Sa | Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique |
| BRPI0807836A2 (pt) * | 2007-02-06 | 2014-08-05 | Novartis Ag | " derivados de 1-benzenossulfonil-1h-indol como inibidores da atividade de ccr9 ". |
| HRP20150882T1 (hr) * | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| WO2011069298A1 (en) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| JP6249966B2 (ja) * | 2012-02-29 | 2017-12-20 | ケモセントリックス， インコーポレイテッド | アザ−アリール１ｈ−ピラゾール−１−イルベンゼンスルホンアミド |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
| CN108698991B (zh) | 2016-01-20 | 2022-08-23 | 凯莫森特里克斯股份有限公司 | 2-氧代吲哚化合物 |
-
2017
- 2017-01-18 CN CN201780007677.XA patent/CN108698991B/zh active Active
- 2017-01-18 EP EP17741838.1A patent/EP3405455B1/en active Active
- 2017-01-18 BR BR112018014666-8A patent/BR112018014666B1/pt active IP Right Grant
- 2017-01-18 MA MA043799A patent/MA43799A/fr unknown
- 2017-01-18 ES ES17741838T patent/ES2985738T3/es active Active
- 2017-01-18 SG SG11201806153QA patent/SG11201806153QA/en unknown
- 2017-01-18 TW TW106101711A patent/TWI729059B/zh active
- 2017-01-18 WO PCT/US2017/013899 patent/WO2017127409A1/en not_active Ceased
- 2017-01-18 NZ NZ744468A patent/NZ744468A/en unknown
- 2017-01-18 US US15/408,896 patent/US20170204087A1/en not_active Abandoned
- 2017-01-18 MX MX2018008895A patent/MX378739B/es unknown
- 2017-01-18 RU RU2018129849A patent/RU2743747C2/ru active
- 2017-01-18 AU AU2017209023A patent/AU2017209023B2/en active Active
- 2017-01-18 JP JP2018537816A patent/JP6898334B6/ja active Active
- 2017-01-18 KR KR1020187023830A patent/KR102799183B1/ko active Active
- 2017-01-19 AR ARP170100150A patent/AR107398A1/es active IP Right Grant
-
2018
- 2018-03-07 US US15/914,900 patent/US10421748B2/en active Active
- 2018-07-17 IL IL260635A patent/IL260635B/en active IP Right Grant
- 2018-07-24 ZA ZA2018/04966A patent/ZA201804966B/en unknown
-
2019
- 2019-07-29 US US16/524,618 patent/US10759789B2/en active Active
-
2020
- 2020-07-17 US US16/932,114 patent/US11434230B2/en active Active
-
2022
- 2022-08-01 US US17/816,614 patent/US12139475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107398A1 (es) | Compuestos de 2-oxindol | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR119454A2 (es) | COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR093515A1 (es) | Triazolopirazinas | |
| AR104362A1 (es) | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios | |
| AR102537A1 (es) | Agentes inmunomoduladores | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR099646A1 (es) | Fotoestabilizantes de aminas impedidas | |
| AR100137A1 (es) | Compuestos 4-amino-imidazoquinolina | |
| AR089727A1 (es) | Compuesto de pirazin-carboxamida | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR095421A1 (es) | Moduladores de p2x7 | |
| AR092869A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| MX2016014197A (es) | 4-fenilpiperidinas sustituidas, su preparacion y uso. | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR100439A1 (es) | Derivados de carboxamida | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |